Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) Tax Provisions (2022 - 2025)

Sunshine Biopharma (SBFM) has disclosed Tax Provisions for 4 consecutive years, with -$137438.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Tax Provisions fell 163.86% year-over-year to -$137438.0, compared with a TTM value of -$515502.0 through Sep 2025, down 551.62%, and an annual FY2024 reading of -$234858.0, down 159.43% over the prior year.
  • Tax Provisions was -$137438.0 for Q3 2025 at Sunshine Biopharma, up from -$209166.0 in the prior quarter.
  • Across five years, Tax Provisions topped out at $233304.0 in Q4 2022 and bottomed at -$343691.0 in Q2 2024.
  • Average Tax Provisions over 4 years is $570.58, with a median of $31652.5 recorded in 2023.
  • Peak annual rise in Tax Provisions hit 425.53% in 2024, while the deepest fall reached 492.0% in 2024.
  • Year by year, Tax Provisions stood at $233304.0 in 2022, then decreased by 5.59% to $220267.0 in 2023, then tumbled by 158.45% to -$128737.0 in 2024, then decreased by 6.76% to -$137438.0 in 2025.
  • Business Quant data shows Tax Provisions for SBFM at -$137438.0 in Q3 2025, -$209166.0 in Q2 2025, and -$40161.0 in Q1 2025.